Apple Vision Pro Cataract Surgery Use Is Growing, But Patient Benefits Unproven
One surgeon has used the headset in hundreds of procedures. A major health system just launched a formal study. Here's what the evidence actually supports and what it doesn't.
Apple Vision Pro cataract surgery has moved from one-time demonstration to repeated clinical practice in ophthalmology. MacRumors reported today that Dr. Eric Rosenberg of SightMD performed his first Vision Pro-assisted cataract procedure in October 2025 and has since used the approach across hundreds of additional cases through ScopeXR, a surgical visualization platform he co-developed for the headset. That volume means one surgeon now relies on the technology routinely, not just for selected demonstrations.
The broader picture involves three developments spanning roughly 18 months. A nine-patient exploratory pilot published in April 2025 established that Apple Vision Pro could be integrated with real-time 3D surgical imaging during intraocular procedures (Springer, one year ago). Rosenberg's repeated real-world use built on that foundation. Now Sharp HealthCare has launched what it describes, in its own announcement, as one of the first IRB-approved prospective clinical evaluations of the technology in ocular microsurgery (PR Newswire, two weeks ago).
What none of this has produced is evidence that patients fare better. That distinction matters more than the adoption story.
What evidence exists on Apple Vision Pro cataract surgery
The clinical record is thin but not empty. The strongest published data comes from a pilot study of nine intraocular surgeries conducted between September and December 2024, all performed by a single fellowship-trained vitreoretinal surgeon (Springer, one year ago). The study was framed as exploratory from the outset the goal was feasibility, not a comparison against standard technique.
In the cataract cases, the Vision Pro was used to superimpose retinography, OCT imaging, and optical biometry data into a single mixed-reality view before surgery, consolidating multiple reference screens into one wearable display (Springer, one year ago). The paper did not report patient outcome data or adverse events, so the published record supports "used in intraocular surgery without described harms" not a safety determination in any clinical sense.
Rosenberg's case volume adds a different kind of signal. Hundreds of procedures over roughly six months suggests a surgeon who has integrated the technology into standard practice, not one testing it cautiously. But the sourcing is worth noting: that figure comes from a media report covering Rosenberg's own platform (MacRumors, today). There is no published case series, no registry data, and the available reports do not provide an adverse-event breakdown. Volume of use and clinical evidence are not the same thing.
Taken together, the best available evidence to date is this: Apple Vision Pro has been used in cataract surgery repeatedly, by at least two surgeons, with no harms described in the sources reviewed. What it has not produced is a controlled comparison showing it changes what happens to patients.
How the headset functions in the operating room
Apple Vision Pro does not perform surgery. It functions as a new visualization layer on top of existing precision surgical hardware, closer to replacing a wall of reference monitors with a wearable heads-up display than to introducing a new surgical instrument.
At Sharp HealthCare, surgeons use the headset alongside ClearSurgery's ClearSphere application and a ZEISS ARTEVO digital surgical microscope (PR Newswire, two weeks ago). The 2025 pilot used a comparable hardware configuration: a ZEISS ARTEVO/Resight microscope, a 55-inch 4K HDR 3D monitor, and dual 4K cameras enabling heads-up surgery, where the surgeon views a high-definition 3D feed rather than looking through a traditional eyepiece (Springer, one year ago).
The practical change for the surgeon: imaging data that would typically live on separate screens between procedure steps gets consolidated into a single wearable display. For ophthalmologists doing high volumes of cataract cases in a fixed bent posture, that matters. Sharp principal investigator Dr. Tommy Korn said the study aims to understand "how spatial computing may be used in eye surgery workflows while supporting surgeon well-being" (PR Newswire, two weeks ago). Ergonomics is a formal study endpoint, not a side observation.
Sharp's IRB study: what it's designed to answer, and what it isn't
The study's full title is "Evaluation of Head Mounted Spatial Computing and 3D Visualization in Ocular Microsurgery: A Feasibility and Safety Study" (PR Newswire, two weeks ago). Feasibility and safety studies are not designed to prove a technology outperforms existing approaches. They are designed to determine whether a technology can be integrated into clinical workflows without causing harm, and whether it functions well enough to justify a larger trial.
The study is being conducted at Sharp Otay Lakes Ambulatory Surgery Center in Chula Vista, a community setting rather than an academic medical center. Dr. Korn said the location was chosen deliberately: "In a region like San Diego, where cataract surgery is commonly needed, evaluating this technology in a community-based setting allows us to better understand how it performs in real-world patient care" (PR Newswire, two weeks ago). The evaluative domains Korn described cover surgical visualization quality, workflow integration, and surgeon well-being. What the study will not produce, by design: evidence that spatial computing-assisted cataract surgery yields better visual acuity, lower complication rates, or faster recovery than standard technique.
That's also what the field is still missing entirely. No published study has measured operative time with or without the headset, tracked conversion or failure rates, quantified surgeon fatigue across sessions, or collected data on the learning curve for adoption. Those are the endpoints that would let a surgical department make a real clinical case for the technology, and none of them exist in the literature yet.
One more piece of context worth having: Rosenberg co-developed the ScopeXR platform his surgeries depend on. Sharp's announcement promotes its own Spatial Computing Center of Excellence. ClearSurgery's software is central to the Sharp study. None of that disqualifies the work, but anyone evaluating these findings should have the full picture.
What comes next
Sharp's study represents a meaningful step: structured data collection, IRB oversight, a defined protocol. Dr. Korn put it plainly: "We are conducting this study carefully and responsibly to generate clinical data that helps us understand how spatial computing technology may be used safely in surgical eye care" (PR Newswire, two weeks ago).
The technology has cleared one threshold, not two. Safe enough to study formally: yes. Demonstrably better for patients: not yet established.
The next threshold worth watching is whether Sharp's results include any patient outcome data alongside the workflow and ergonomics findings, and whether independent groups begin replicating the approach outside of institutions with a direct stake in the platforms involved. Until that evidence exists, the story of Apple Vision Pro in eye surgery is a story about how surgeons work, not about how patients recover.
Comments
Be the first, drop a comment!